Dr Reddys partners with South-Korea based HK innoN Corporation

13 May 2022 , 01:33 AM

Dr Reddys Laboratories today announced that it has entered into an exclusive partnership with South Korea-based HK innoN Corporation KOSDAQ 195940 for the supply and commercialisation of HK innoN Corporations patented novel molecule Tegoprazan for gastrointestinal diseases in India and six key Emerging Markets Under this partnership HK innoN Corporation will be responsible for the manufacture and supply of Tegoprazan while Dr Reddys will be responsible for local clinical development registration marketing and sales in the licensed territories The agreement grants Dr Reddys the exclusive rights to develop and commercialise Tegoprazan under its own trademark in these markets for 10 years from the first commercial launch HK innoN Corporation will receive an upfront licensing fee and will be eligible for potential regulatory milestone payments and royalties on net product sales